SciELO - Scientific Electronic Library Online

vol.62 número7Gangrena de Fournier: Nuestra experiencia en 5 años, revisión de la literatura y valoración del índice de severidad de la Gangrena de Fournier índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Archivos Españoles de Urología (Ed. impresa)

versión impresa ISSN 0004-0614


CRUZ GUERRA, Nicolás Alberto. Outcomes of maximal androgen blockade in prostate cancer patients at a health area with type 2 reference hospital (2nd part). quality of life: application of EORTC QLQ-PR25 instrument and global results. Quality-of-life adjusted survival. Pharmaceutical expenses and cost-utility. Arch. Esp. Urol. [online]. 2009, vol.62, n.7, pp.543-570. ISSN 0004-0614.

Objectives: To study quality of life in patients from the health area of Zamora diagnosed of prostate adenocarcinoma between 2000-2005 treated with maximal androgen blockade (MAB). To evaluate the pharmacoeconomics of the treatment. Methods: Basal, 12-month, 24 -month and 36-month application of the health-related quality of life measurement instrument EORTC QLQ-C30 to the population sample (n= 111), as well as a control sample (n= 100). Comparative study of outcomes: between groups; between different time measurements in MAB patients; and inter-categories/-intervals of some variables in patients with hormonal deprivation therapy (third year of follow-up). Analysis of health-related quality of life global outcomes (QLQ-C30 + QLQ-PR25). Description of the pharmaceutical expenses in androgen blockade patients. Cost-utility analysis by means of quality-adjusted life years (QALYs) obtained using preference-based weighted index from the EUROQOL 5-D tool. Results: Hot flushes and sexual field worsening as mean expressions related to hormonal suppression. Treated patients had worse subjective perception of health condition and quality of life, in opposition to non-tumoral individuals. Positive bone scan, was a negative-influence factor on quality of life. Most patients undergoing MAB needed cost-utility figures of less than 5000 Euros/ QALY. Conclusions: There was a negative initial repercussion of MAB on quality of life, although tinged according to the different fields studied. The economic impact of this therapy on overall pharmaceutical expenses is relative.

Palabras clave : Prostate cancer; Hormonal therapy; Quality of life; Health economics.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )


Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons